HIV Care

  • Posted by Vincent Basajja on August 7, 2020 at 12:09 pm

    The HVTN 505 approach to the changing HIV prevention landscape provided a lot of insight. We know the IPM Dapivirine Vaginal ring received positive opinion from EMA. What do you think if it were approved as a new HIV prevention tool for women during the PrEPVacc trial?


    Sylvia Kusemererwa replied 3 years, 9 months ago 2 Members · 1 Reply
  • 1 Reply
  • Sylvia Kusemererwa

    August 10, 2020 at 7:29 pm

    That would be interesting to observe! However, if provided as part of the study design, women would choose between taking a pill and using a ring. Similar to what is being done under the REACH trial, 6 months on pills and 6 months on the ring followed by a crossover.

The forum ‘Clinical Trial Design’ is closed to new discussions and replies.

Start of Discussion
0 of 0 replies June 2018